Dr. Thaker is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4921 Parkview Pl
Saint Louis, MO 63110Phone+1 314-362-3181Fax+1 866-282-1113- Is this information wrong?
Summary
- I am an Associate Professor in the Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University in St. Louis, Missouri as well as a Clinician and a Research Member at the Siteman Cancer Center of Washington University. I trained as a cancer biologist during my fellowship at MD Anderson Cancer Center with emphasis in cell and molecular biology including angiogenesis and invasion in ovarian cancer. Now I am interested in novel therapeutics in all gynecologic cancers and have led national as well as institutional clinical trials in ovarian, cervical, and endometrial malignancies. Currently, I run our Division’s clinical trial research efforts.
Education & Training
- University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology, 2006
- University of TexasMS, Cancer Biology, 2004
- University of Pennsylvania Health SystemResidency, Obstetrics and Gynecology, 1999 - 2002
- Drexel University College of Medicine/Hahnemann University HospitalResidency, Obstetrics and Gynecology, 1997 - 1999
- MCP-Hahnemann College of MedicineClass of 1997, MD
- Villanova UniversityBA, Biology, 1995
Certifications & Licensure
- IL State Medical License 2020 - 2026
- MO State Medical License 2006 - 2025
- TX State Medical License 2003 - 2016
- PA State Medical License 1998 - 2012
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Outstanding Publication Award for 2016 of an NRG Oncology Publication on cervical cancer in Annals of Oncology 2017
- Certificate of Excellence in Reviewing Editors of Gynecologic Oncology and Gynecologic Oncology Case Reports, 2014
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012
- Join now to see all
Clinical Trials
- A Phase I Study of Bi-Weekly rBBX-01 in Patients With Solid Tumors Start of enrollment: 2008 Oct 01
- Biobehavioral-Cytokine Interactions in Ovarian Cancer Start of enrollment: 2003 Aug 01
- Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients Start of enrollment: 2010 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 55 citationsMulticenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancerIsrael Zighelboim, Jason D. Wright, Feng Gao, Ashley S. Case, L. Stewart Massad
Gynecologic Oncology. 2013-07-01 - 18 citationsPhase I Trial of Stereotactic MRI-Guided Online Adaptive Radiation Therapy (SMART) for the Treatment of Oligometastatic Ovarian Cancer.Lauren E. Henke, Jennifer A. Stanley, Clifford G. Robinson, A. Srivastava, Jessika Contreras
International Journal of Radiation Oncology, Biology, Physics. 2021-08-30 - 24 citationsStress and burnout among gynecologic oncologists: A Society of Gynecologic Oncology Evidence-based Review and Recommendations.Ilana Cass, Linda R. Duska, Stephanie V. Blank, Georgina Cheng, Nefertiti C. duPont
Gynecologic Oncology. 2016-11-01
Journal Articles
- Modified Frailty Index Is Predictive of Wound Complications in Obese Patients Undergoing Gynecologic Surgery via a Midline Vertical IncisionPremal Thaker, MD, Gynecologic Oncology
- Life Stress as a Risk Factor for Sustained Anxiety and Cortisol Dysregulation During the First Year of Survivorship in Ovarian CancerAnil K Sood, Premal H Thaker, Laila Dahmoush, Cancer
- Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian CancerIan S Hagemann, Premal H Thaker, Carolyn K McCourt, Katherine C Fuh, David G Mutch, Andrea R Hagemann, Matthew A Powell, Clinical Cancer Research
- Join now to see all
Press Mentions
- Celsion Corporation (NASDAQ:CLSN) Presents A Poster Highlighting Its Phase I and II OVATION 2 Clinical Trial in Advanced Ovarian Cancer with GEN-1 at A VAM on Women’s CancerApril 20th, 2021
- Poster on Celsion Corporation’s Phase I/II OVATION 2 Study to Be Presented at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s CancerMarch 2nd, 2021
- Celsion's GEN-1 Immunotherapy Highlighted in Oppenheimer's Expert Call on Ovarian Cancer Treatment Landscape and Emerging OpportunitiesAugust 9th, 2019
- Join now to see all
Committees
- Member, Ovarian Committee, NRG Oncolgoy Group 2011 - 2018
- Member, Phase I Committee, NRG Oncology Group 2007 - 2018
Research History
- Biobehavioral Influences on Ovarian Cancer Progression: Role of Chemoresistance2016 - 2020
- Leading Academic Participating SitesThe goal of this project is to improve patient accrual to clinical trials at NCI designated cancer centers.2014 - 2019
- Gynecologic Oncology Support fundThe goal of the project is to support research in ovarian cancer targeting the identification of clinically relevant targets in ovarian cancer.2017 - 2018
- Molecular Oncology Training GrantI serve as a clinical mentor to Ph.D. students in order for them to better understand how to translate bench findings in clinical problems.2005 - 2018
Professional Memberships
- Fellow
- Member
Hospital Affiliations
- Barnes-Jewish HospitalSaint Louis, Missouri
- St. Louis Children's HospitalSaint Louis, Missouri
- Barnes-Jewish West County HospitalSaint Louis, Missouri
- Progress West HospitalO Fallon, Missouri
- Siteman Cancer CenterSaint Louis, Missouri
- Barnes-Jewish St. Peters HospitalSaint Peters, Missouri
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: